chr3-128482170-A-C
Variant names:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_032638.5(GATA2):c.1018-226T>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.217 in 599,928 control chromosomes in the GnomAD database, including 14,978 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.23 ( 4195 hom., cov: 33)
Exomes 𝑓: 0.21 ( 10783 hom. )
Consequence
GATA2
NM_032638.5 intron
NM_032638.5 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.0550
Publications
5 publications found
Genes affected
GATA2 (HGNC:4171): (GATA binding protein 2) This gene encodes a member of the GATA family of zinc-finger transcription factors that are named for the consensus nucleotide sequence they bind in the promoter regions of target genes. The encoded protein plays an essential role in regulating transcription of genes involved in the development and proliferation of hematopoietic and endocrine cell lineages. Alternative splicing results in multiple transcript variants.[provided by RefSeq, Mar 2009]
GATA2 Gene-Disease associations (from GenCC):
- deafness-lymphedema-leukemia syndromeInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp
- GATA2 deficiency with susceptibility to MDS/AMLInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- monocytopenia with susceptibility to infectionsInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics
- acute myeloid leukemiaInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- myelodysplastic syndromeInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BP6
Variant 3-128482170-A-C is Benign according to our data. Variant chr3-128482170-A-C is described in ClinVar as Benign. ClinVar VariationId is 1277301.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.249 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GATA2 | NM_032638.5 | c.1018-226T>G | intron_variant | Intron 4 of 5 | ENST00000341105.7 | NP_116027.2 | ||
| GATA2 | NM_001145661.2 | c.1018-226T>G | intron_variant | Intron 5 of 6 | NP_001139133.1 | |||
| GATA2 | NM_001145662.1 | c.1018-268T>G | intron_variant | Intron 4 of 5 | NP_001139134.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.230 AC: 35021AN: 152082Hom.: 4192 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
35021
AN:
152082
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.212 AC: 95002AN: 447728Hom.: 10783 AF XY: 0.206 AC XY: 48139AN XY: 234070 show subpopulations
GnomAD4 exome
AF:
AC:
95002
AN:
447728
Hom.:
AF XY:
AC XY:
48139
AN XY:
234070
show subpopulations
African (AFR)
AF:
AC:
3063
AN:
12258
American (AMR)
AF:
AC:
4012
AN:
17800
Ashkenazi Jewish (ASJ)
AF:
AC:
2501
AN:
13194
East Asian (EAS)
AF:
AC:
3884
AN:
29316
South Asian (SAS)
AF:
AC:
4714
AN:
44832
European-Finnish (FIN)
AF:
AC:
5693
AN:
26958
Middle Eastern (MID)
AF:
AC:
433
AN:
1890
European-Non Finnish (NFE)
AF:
AC:
64956
AN:
275986
Other (OTH)
AF:
AC:
5746
AN:
25494
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.512
Heterozygous variant carriers
0
3459
6918
10378
13837
17296
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
526
1052
1578
2104
2630
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.230 AC: 35046AN: 152200Hom.: 4195 Cov.: 33 AF XY: 0.226 AC XY: 16849AN XY: 74408 show subpopulations
GnomAD4 genome
AF:
AC:
35046
AN:
152200
Hom.:
Cov.:
33
AF XY:
AC XY:
16849
AN XY:
74408
show subpopulations
African (AFR)
AF:
AC:
10488
AN:
41516
American (AMR)
AF:
AC:
3418
AN:
15306
Ashkenazi Jewish (ASJ)
AF:
AC:
619
AN:
3468
East Asian (EAS)
AF:
AC:
691
AN:
5180
South Asian (SAS)
AF:
AC:
486
AN:
4832
European-Finnish (FIN)
AF:
AC:
2211
AN:
10596
Middle Eastern (MID)
AF:
AC:
78
AN:
294
European-Non Finnish (NFE)
AF:
AC:
16274
AN:
67986
Other (OTH)
AF:
AC:
486
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1403
2806
4208
5611
7014
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
348
696
1044
1392
1740
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
465
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
Sep 14, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.